Literature DB >> 15566511

Risk factors for hepatocellular carcinoma in Hepatitis C patients with sustained virologic response to interferon therapy.

Yoshiaki Iwasaki1, Kouichi Takaguchi, Hiroshi Ikeda, Yasuhiro Makino, Yasuyuki Araki, Masaharu Ando, Haruhiko Kobashi, Toshitsugu Kobatake, Ryoji Tanaka, Minoru Tomita, Tomonori Senoh, Mitsuhiko Kawaguchi, Toshinari Shimoe, Koji Manabe, Keiji Kita, Junnosuke Shimamura, Kohsaku Sakaguchi, Yasushi Shiratori.   

Abstract

BACKGROUND: Although a variety of papers demonstrated inhibited hepatocarcinogenesis with interferon (IFN) therapy for chronic hepatitis C, a small number of hepatocellular carcinomas (HCCs) were still observed even in sustained virologic responders. AIMS: To clarify factors affecting the development of HCC, we analyzed the frequency of HCC in sustained virologic responders over a long-term observation period.
METHODS: Seven hundred and ninety-two out of the 2623 IFN-treated hepatitis C patients who had undergone liver biopsy showed sustained virologic response. Screening for development of HCC was performed periodically during an average follow-up of 5.1 years. Fibrosis of the pretreatment liver biopsy sample was graded. Risk factors for HCC were analyzed by using Cox proportional hazards regression.
RESULTS: Of 792 patients, 23 developed HCC. Univariate analysis showed that stage of hepatic fibrosis, age, and alcohol consumption were significantly associated with a risk of HCC (P<0.001). There was a significant difference in the cumulative incidence between patients stratified according to these variables (P<0.001).
CONCLUSIONS: Pretreatment hepatic fibrosis score, age, and alcohol consumption may affect development of HCC even in sustained virologic responders. Thus, patients with these factors should be carefully followed even after eradication of the virus.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15566511     DOI: 10.1111/j.1478-3231.2004.0956.x

Source DB:  PubMed          Journal:  Liver Int        ISSN: 1478-3223            Impact factor:   5.828


  19 in total

1.  Intrahepatic cholangiocellular carcinoma and hepatocellular carcinoma developed after a 6-year sustained virological response to interferon therapy for chronic hepatitis C.

Authors:  Shinji Takashimizu; Sei-Ichiro Kojima; Junko Nagata; Yasuhiro Nishizaki; Tatehiro Kagawa; Koichi Shiraishi; Tetsuya Mine; Jun-Ichi Kaneko; Norihiro Kokudo; Norihito Watanabe
Journal:  Clin J Gastroenterol       Date:  2011-03-24

2.  Effect of previous interferon treatment on outcome after curative treatment for hepatitis C virus-related hepatocellular carcinoma.

Authors:  Hirokazu Miyatake; Yoshiyuki Kobayashi; Yoshiaki Iwasaki; Shin-Ichiro Nakamura; Hideki Ohnishi; Kenji Kuwaki; Junichi Toshimori; Hiroaki Hagihara; Kazuhiro Nouso; Kazuhide Yamamoto
Journal:  Dig Dis Sci       Date:  2011-10-12       Impact factor: 3.199

3.  Risk of Hepatocellular Carcinoma in Patients with Hepatitis C Virus Who Achieved Sustained Virological Response.

Authors:  M Kudo
Journal:  Liver Cancer       Date:  2016-05-03       Impact factor: 11.740

4.  Eradication of hepatitis C virus reduces the risk of hepatocellular carcinoma in patients with compensated cirrhosis.

Authors:  José Velosa; Fátima Serejo; Rui Marinho; Joana Nunes; Helena Glória
Journal:  Dig Dis Sci       Date:  2011-03-05       Impact factor: 3.199

5.  Usefulness of combination therapy with Daclatasvir plus Asunaprevir in chronic hepatitis C patients with chronic kidney disease.

Authors:  Norihiko Morisawa; Yohei Koshima; Jun-Ichi Satoh; Yukio Maruyama; Satoru Kuriyama; Takashi Yokoo; Morimasa Amemiya
Journal:  Clin Exp Nephrol       Date:  2016-10-22       Impact factor: 2.801

6.  Hepatic steatosis as a possible risk factor for the development of hepatocellular carcinoma after eradication of hepatitis C virus with antiviral therapy in patients with chronic hepatitis C.

Authors:  Atsushi Tanaka; Satoko Uegaki; Hiroko Kurihara; Kiyoshi Aida; Masaki Mikami; Ikuo Nagashima; Junji Shiga; Hajime Takikawa
Journal:  World J Gastroenterol       Date:  2007-10-21       Impact factor: 5.742

7.  Hepatocellular carcinoma after sustained virologic response in hepatitis C patients without cirrhosis on a pretreatment liver biopsy.

Authors:  Justin L Sewell; Kristine M Stick; Alexander Monto
Journal:  Eur J Gastroenterol Hepatol       Date:  2009-02       Impact factor: 2.566

Review 8.  Occurrence of hepatocellular carcinoma 24 years after successful interferon therapy in a patient with chronic hepatitis C: a case report.

Authors:  Yuichi Yoshida; Miki Yonezawa; Takuya Okamoto; Yudai Fujiwara; Akiko Suzuki; Yuji Suzuki; Kei Endo; Keisuke Kakisaka; Takayoshi Oikawa; Hidekatsu Kuroda; Akio Miyasaka; Yasuhiro Takikawa
Journal:  Clin J Gastroenterol       Date:  2018-10-19

9.  Heavy Drinking and Treatment among HIV/HCV Co-Infected Patients.

Authors:  Jennifer C Elliott; Noga Shalev; Deborah S Hasin
Journal:  J Subst Abus Alcohol       Date:  2018-07-26

10.  A serum "sweet-doughnut" protein facilitates fibrosis evaluation and therapy assessment in patients with viral hepatitis.

Authors:  Atsushi Kuno; Yuzuru Ikehara; Yasuhito Tanaka; Kiyoaki Ito; Atsushi Matsuda; Satoru Sekiya; Shuhei Hige; Michiie Sakamoto; Masayoshi Kage; Masashi Mizokami; Hisashi Narimatsu
Journal:  Sci Rep       Date:  2013-01-15       Impact factor: 4.379

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.